Ding G W, Ye S D, Hei F X, Lian Q L, Pei X D, Bai J Y, Zhou D, Yang Q, Hui S, Wang W, Tu A X, Pang L
Division of HCV and STD Prevention and Treatment, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
Department of High Risk Population Intervention, Institute of AIDS/STD Prevention and Treatment, Fujian Provincial Center for Disease Control and Prevention, Fuzhou 350001, China.
Zhonghua Liu Xing Bing Xue Za Zhi. 2019 Jan 10;40(1):41-45. doi: 10.3760/cma.j.issn.0254-6450.2019.01.009.
To understand the prevalence of hepatitis C virus (HCV) infection in 5 populations in China during 2016-2017 and provide evidence for the estimation of prevalence trend of hepatitis C and evaluation on the prevention and control effect. A total of 87 national sentinel surveillance sites for hepatitis C were set up in 31 provinces (autonomous regions and municipalities) of China to obtain the information about HCV infection prevalence in 5 populations, including volunteer blood donors, people receiving physical examination, patients receiving invasive diagnosis and treatment, patients receiving hemodialysis, and clients visiting family planning outpatient clinics. From April to June, 2016 and 2017, cross-sectional surveys were repeatedly conducted in the 5 populations and blood samples were collected from them for HCV antibody detection. In 2016, 86 sentinel sites completed the surveillance (one sentinel site was not investigated), and 115 841 persons were surveyed. The overall HCV positive rate was 0.38 (442/115 841, 95: 0.23-0.53). In 2017, all the 87 sentinel sites completed the surveillance, and 120 486 persons were surveyed. The overall HCV positive rate was 0.37 (449/120 486, 95: 0.23-0.52). In 2016 and 2017, the anti-HCV positive rates were 4.46 (223/5 005, 95: 2.18-6.73) and 4.39 (216/4 919, 95: 2.29-6.50) respectively in hemodialysis patients, 0.85 (44/5 200, 95: 0.27-1.42) and 0.70 (36/5 150, 95: 0.15-1.24) respectively in patients receiving invasive diagnosis and treatment and remained to be ≤0.25 in volunteer blood donors, people receiving physical examination and clients visiting family planning outpatient clinics. Results for the comparison of the anti-HCV positive rates in the 5 populations indicated that the differences were significant (=23.091, <0.001 in 2016 and =20.181, <0.001 in 2017). Data from the sentinel surveillance of HCV infection on prevalence in China showed that the anti-HCV positive rates varied in the 5 populations during 2016-2017. The anti-HCV positive rate appeared the highest in the hemodialysis patients, followed by that in the patients receiving invasive diagnosis and treatment, and the prevalence of HCV infection in other 3 populations were at low levels.
了解2016 - 2017年中国5类人群丙型肝炎病毒（HCV）感染流行状况，为丙型肝炎流行趋势估计及防控效果评价提供依据。在中国31个省（自治区、直辖市）共设立87个全国丙型肝炎哨点监测点，获取包括无偿献血者、体检人群、接受侵入性诊断治疗的患者、接受血液透析的患者以及计划生育门诊就诊者5类人群的HCV感染流行信息。2016年4月至6月以及2017年同期，对这5类人群反复开展横断面调查并采集血样进行HCV抗体检测。2016年，86个哨点完成监测（1个哨点未调查），共调查115 841人，HCV总体阳性率为0.38（442/115 841，95%CI：0.23 - 0.53）。2017年，87个哨点全部完成监测，共调查120 486人，HCV总体阳性率为0.37（449/120 486，95%CI：0.23 - 0.52）。2016年和2017年，血液透析患者抗-HCV阳性率分别为4.46（223/5 005，95%CI：2.18 - 6.73）和4.39（216/4 919，95%CI：2.29 - 6.50），接受侵入性诊断治疗的患者分别为0.85（44/5 200，95%CI：0.27 - 1.42）和0.70（36/5 150，95%CI：0.15 - 1.24），无偿献血者、体检人群和计划生育门诊就诊者的抗-HCV阳性率均≤0.25。5类人群抗-HCV阳性率比较结果显示，差异有统计学意义（2016年χ² = 23.091，P < 0.001；2017年χ² = 20.181，P < 0.001）。中国HCV感染哨点监测的流行数据显示，2016 - 2017年5类人群抗-HCV阳性率存在差异，血液透析患者抗-HCV阳性率最高，其次为接受侵入性诊断治疗的患者，其他3类人群HCV感染率处于较低水平。
